Imfinzi
AstraZeneca’s Imfinzi, Tremelimumab Combo Significantly Improves Overall Survival in Phase 3 Trials
2021-10-18
AstraZeneca Voluntarily Withdraws Checkpoint Inhibitor Approved for Bladder Cancer Indication
2021-02-25
LATEST
VintaBio Showcases High-Yield VintaProcess Platform for Gene Therapy Vector Production at ASGCT 2025
2025-05-15
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15